Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

Anti-COVID19 VaccinaTion AKS-452 BOOSTER (ACT-BOOSTER Study)

  • Read more about Anti-COVID19 VaccinaTion AKS-452 BOOSTER (ACT-BOOSTER Study)

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

  • Read more about Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

VSL#3® vs Placebo in the Treatment of Fatigue and Other Symptoms in Long Covid (DELong#3)

  • Read more about VSL#3® vs Placebo in the Treatment of Fatigue and Other Symptoms in Long Covid (DELong#3)

Prognostic Value of IgM in Covid-19 Infection

  • Read more about Prognostic Value of IgM in Covid-19 Infection

A Pilot Study of a PhysiOthErapy-based Tailored Intervention for Long COVID (COVID-19)

  • Read more about A Pilot Study of a PhysiOthErapy-based Tailored Intervention for Long COVID (COVID-19)

A Real-world Retrospective Study of Disease Outcomes in Non-severe COVID-19 Patient

  • Read more about A Real-world Retrospective Study of Disease Outcomes in Non-severe COVID-19 Patient

Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination

  • Read more about Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination

Risk Factors for Community- and Workplace Transmission of COVID-19

  • Read more about Risk Factors for Community- and Workplace Transmission of COVID-19

Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients

  • Read more about Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients

Pulmonary Vascular Dysfunction as a Cause of Persistent Exertional Dyspnea After Coronavirus Disease (COVID-19)

  • Read more about Pulmonary Vascular Dysfunction as a Cause of Persistent Exertional Dyspnea After Coronavirus Disease (COVID-19)

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 133
  • Page 134
  • Page 135
  • Page 136
  • Current page 137
  • Page 138
  • Page 139
  • Page 140
  • Page 141
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA